# A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

> **NCT04864977** · PHASE4 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Type 2 Diabetes
- Type 2 Diabetes Treated With Insulin

## Interventions

- **DRUG:** Basal Insulin

## Key facts

- **NCT ID:** NCT04864977
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-16
- **Primary completion:** 2022-06-06
- **Final completion:** 2022-06-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was stopped prior to study start date due to business decision.
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864977, "A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04864977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*